CTCF and EGR1 Suppress Breast Cancer Cell Migration Through Transcriptional Control of Nm23-H1

Overview

Journal Sci Rep

Specialty Science

Date 2021 Jan 13

PMID 33436746

Citations 22

Authors

Ka Ming Wong

Jiaxing Song

Yung H Wong

Affiliations

Soon will be listed here.

Abstract

Tumor metastasis remains an obstacle in cancer treatment and is responsible for most cancer-related deaths. Nm23-H1 is one of the first metastasis suppressor proteins discovered with the ability to inhibit metastasis of many cancers including breast, colon, and liver cancer. Although loss of Nm23-H1 is observed in aggressive cancers and correlated with metastatic potential, little is known regarding the mechanisms that regulate its cellular level. Here, we examined the mechanisms that control Nm23-H1 expression in breast cancer cells. Initial studies in aggressive MDA-MB-231 cells (expressing low Nm23-H1) and less invasive MCF-7 cells (expressing high Nm23-H1) revealed that mRNA levels correlated with protein expression, suggesting that transcriptional mechanisms may control Nm23-H1 expression. Truncational analysis of the Nm23-H1 promoter revealed a proximal and minimal promoter that harbor putative binding sites for transcription factors including CTCF and EGR1. CTCF and EGR1 induced Nm23-H1 expression and reduced cell migration of MDA-MB-231 cells. Moreover, CTCF and EGR1 were recruited to the Nm23-H1 promoter in MCF-7 cells and their expression correlated with Nm23-H1 levels. This study indicates that loss of Nm23-H1 in aggressive breast cancer is apparently caused by downregulation of CTCF and EGR1, which potentially drive Nm23-H1 expression to promote a less invasive phenotype.

Citing Articles

EGR1 inhibits clear cell renal cell carcinoma proliferation and metastasis via the MAPK15 pathway.

Peng N, Cai Y, Chen D, Deng L, Zhang Z, Li W Oncol Res. 2025; 33(2):347-356.

PMID: 39866235 PMC: 11753989. DOI: 10.32604/or.2024.056039.

Footprint-C reveals transcription factor modes in local clusters and long-range chromatin interactions.

Liu X, Wei H, Zhang Q, Zhang N, Wu Q, Xu C Nat Commun. 2024; 15(1):10922.

PMID: 39738122 PMC: 11686180. DOI: 10.1038/s41467-024-55403-7.

Alleviating role of ketamine in breast cancer cell-induced osteoclastogenesis and tumor bone metastasis-induced bone cancer pain through an SRC/EGR1/CST6 axis.

Zhang X, Zhang Y, Du W BMC Cancer. 2024; 24(1):1535.

PMID: 39695463 PMC: 11656615. DOI: 10.1186/s12885-024-13290-7.

Immune alterations and overexpression of CTCF in endometrial carcinoma: insights from molecular subtyping.

Wei C, Chen G, Chen K, Fang S, He H Cancer Cell Int. 2024; 24(1):392.

PMID: 39623397 PMC: 11613940. DOI: 10.1186/s12935-024-03576-y.

Chronic stress promotes non-small cell lung cancer (NSCLC) progression through circMBOAT2 upregulation mediated by CTCF.

Zhou T, Chen Z, Chen Y, Li C, Xiao Z, Duan J Cancer Gene Ther. 2024; 31(11):1721-1733.

PMID: 39300219 PMC: 11567882. DOI: 10.1038/s41417-024-00830-3.

References

Lin K, Shieh H, Hsu H . Negative regulation of the antimetastatic gene Nm23-H1 by thyroid hormone receptors. Endocrinology. 2000; 141(7):2540-7. DOI: 10.1210/endo.141.7.7570. View

Dillon R, Brown S, Ling C, Shioda T, Muller W . An EGR2/CITED1 transcription factor complex and the 14-3-3sigma tumor suppressor are involved in regulating ErbB2 expression in a transgenic-mouse model of human breast cancer. Mol Cell Biol. 2007; 27(24):8648-57. PMC: 2169423. DOI: 10.1128/MCB.00866-07. View

Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, Klingenhoff A . MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics. 2005; 21(13):2933-42. DOI: 10.1093/bioinformatics/bti473. View

Ozdemir F, Koksal M, Ozmen V, Aydin I, Buyru N . Mutations and Krüppel-like factor 6 (KLF6) expression levels in breast cancer. Tumour Biol. 2014; 35(6):5219-25. DOI: 10.1007/s13277-014-1678-6. View

Hartsough M, Steeg P . Nm23/nucleoside diphosphate kinase in human cancers. J Bioenerg Biomembr. 2002; 32(3):301-8. DOI: 10.1023/a:1005597231776. View

Yang L, Lee M, Leung M, Wong Y . Regulator of G protein signaling 20 enhances cancer cell aggregation, migration, invasion and adhesion. Cell Signal. 2016; 28(11):1663-72. DOI: 10.1016/j.cellsig.2016.07.017. View

Chang C, Zhu X, Thoraval D, Ungar D, Rawwas J, Hora N . Nm23-H1 mutation in neuroblastoma. Nature. 1994; 370(6488):335-6. DOI: 10.1038/370335a0. View

Bevilacqua G, Sobel M, Liotta L, Steeg P . Association of low nm23 RNA levels in human primary infiltrating ductal breast carcinomas with lymph node involvement and other histopathological indicators of high metastatic potential. Cancer Res. 1989; 49(18):5185-90. View

Gerloff A, Dittmer A, Oerlecke I, Holzhausen H, Dittmer J . Protein expression of the Ets transcription factor Elf-1 in breast cancer cells is negatively correlated with histological grading, but not with clinical outcome. Oncol Rep. 2011; 26(5):1121-5. DOI: 10.3892/or.2011.1409. View

10.

Fishilevich S, Nudel R, Rappaport N, Hadar R, Plaschkes I, Iny Stein T . GeneHancer: genome-wide integration of enhancers and target genes in GeneCards. Database (Oxford). 2017; 2017. PMC: 5467550. DOI: 10.1093/database/bax028. View

11.

Fiore L, Ganguly S, Sledziona J, Cibull M, Wang C, Richards D . c-Abl and Arg induce cathepsin-mediated lysosomal degradation of the NM23-H1 metastasis suppressor in invasive cancer. Oncogene. 2013; 33(36):4508-4520. PMC: 3979510. DOI: 10.1038/onc.2013.399. View

12.

Marino N, Nakayama J, Collins J, Steeg P . Insights into the biology and prevention of tumor metastasis provided by the Nm23 metastasis suppressor gene. Cancer Metastasis Rev. 2012; 31(3-4):593-603. PMC: 7479534. DOI: 10.1007/s10555-012-9374-8. View

13.

Leone A, Flatow U, King C, Sandeen M, Margulies I, Liotta L . Reduced tumor incidence, metastatic potential, and cytokine responsiveness of nm23-transfected melanoma cells. Cell. 1991; 65(1):25-35. DOI: 10.1016/0092-8674(91)90404-m. View

14.

Hung C, Wang Y, Chuang J, Young M, Liaw H, Chang W . Nm23-H1-stabilized hnRNPA2/B1 promotes internal ribosomal entry site (IRES)-mediated translation of Sp1 in the lung cancer progression. Sci Rep. 2017; 7(1):9166. PMC: 5567229. DOI: 10.1038/s41598-017-09558-7. View

15.

Tate J, Bamford S, Jubb H, Sondka Z, Beare D, Bindal N . COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 2018; 47(D1):D941-D947. PMC: 6323903. DOI: 10.1093/nar/gky1015. View

16.

LARKIN M, Blackshields G, Brown N, Chenna R, McGettigan P, McWilliam H . Clustal W and Clustal X version 2.0. Bioinformatics. 2007; 23(21):2947-8. DOI: 10.1093/bioinformatics/btm404. View

17.

Chakrabarti R, Hwang J, Blanco M, Wei Y, Lukacisin M, Romano R . Elf5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2. Nat Cell Biol. 2012; 14(11):1212-22. PMC: 3500637. DOI: 10.1038/ncb2607. View

18.

Chen J, Jiang Q, Jiang X, Li D, Jiang X, Wu X . miR-146a promoted breast cancer proliferation and invasion by regulating NM23-H1. J Biochem. 2019; 167(1):41-48. DOI: 10.1093/jb/mvz079. View

19.

Okubo T, Inokuma S, Takeda S, Itoyama S, Kinoshita K, Sugawara I . Expression of nm23-H1 gene product in thyroid, ovary, and breast cancers. Cell Biophys. 1995; 26(3):205-13. DOI: 10.1007/BF02791581. View

20.

Riffo-Campos A, Castillo J, Tur G, Gonzalez-Figueroa P, Georgieva E, Rodriguez J . Nucleosome-specific, time-dependent changes in histone modifications during activation of the early growth response 1 (Egr1) gene. J Biol Chem. 2014; 290(1):197-208. PMC: 4281722. DOI: 10.1074/jbc.M114.579292. View